Taro joined UntroD Capital Japan, which manages Real Tech Fund, in 2017. Since October 2026, he has served as Director, Real Tech Fund. He has led investments in and supported portfolio companies including ANSeeN, which enables high-definition X-ray imaging diagnostics and inspection while reducing radiation exposure to 1/1000; AMI, which develops a super stethoscope that assists automated diagnosis of heart disease through analysis of heart sounds and electrocardiograms; UMIAILE, which uses small autonomous boats to enable unmanned operations from seabed observation to defense surveillance; and Japan Superconductor Applied Development (JSA), whose high-temperature superconducting technology supports the realization of nuclear fusion and quantum computers. He also founded Tokyo Nucleic Acid Synthesis and serves as its Representative Director, leading UntroD’s first company-creation initiative.

To advance the startup ecosystem, including government procurement, he contributed to the revision of the SBIR program and was appointed as a Program Manager for the SBIR program of the Ministry of Economy, Trade and Industry (METI).

Prior to joining the company, he was engaged in the research and development of electronic materials at Sumitomo Chemical, and later, as a new business lead, was responsible for the development of medical materials and business planning and execution for regenerative medicine materials. He also handled overseas sales of functional resins in the Southeast Asian market.

He has a Master’s degree in Applied Chemistry from Tokyo University of Agriculture and Technology.